|
🐜
|
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.
27 auth.
E. Stein,
C. Dinardo,
D. Pollyea,
A. Fathi,
G. Roboz,
J. Altman,
R. Stone,
D. DeAngelo,
R. Levine,
I. Flinn,
H. Kantarjian,
R. Collins,
M. Patel,
A. Frankel,
A. Stein,
...
M. Sekeres,
R. Swords,
B. Medeiros,
C. Willekens,
P. Vyas,
A. Tosolini,
Qiang Xu,
R. Knight,
K. Yen,
S. Agresta,
S. de Botton,
M. Tallman
|
10 |
2017 |
10
🐜
|
|
🐜
|
Durable Remissions with Ivosidenib in IDH1‐Mutated Relapsed or Refractory AML
40 auth.
C. Dinardo,
E. Stein,
S. de Botton,
G. Roboz,
J. Altman,
A. Mims,
R. Swords,
R. Collins,
G. Mannis,
D. Pollyea,
W. Donnellan,
A. Fathi,
A. Pigneux,
H. Erba,
G. Prince,
...
A. Stein,
G. Uy,
J. Foran,
E. Traer,
R. Stuart,
M. Arellano,
J. Slack,
M. Sekeres,
C. Willekens,
S. Choe,
Hongfang Wang,
V. Zhang,
K. Yen,
S. Kapsalis,
Hua Yang,
D. Dai,
Bin Fan,
M. Goldwasser,
Hua Liu,
S. Agresta,
Bin Wu,
E. Attar,
M. Tallman,
R. Stone,
H. Kantarjian
|
10 |
2018 |
10
🐜
|
|
🐜
|
Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation
31 auth.
F. Wang,
J. Travins,
B. Delabarre,
V. Penard-Lacronique,
S. Schalm,
Erica Hansen,
K. Straley,
A. Kernytsky,
Wei Liu,
C. Gliser,
Hua Yang,
S. Gross,
Erin Artin,
V. Saada,
E. Mylonas,
...
C. Quivoron,
Janeta Popovici-Muller,
J. Saunders,
F. Salituro,
Shunqi Yan,
Stuart Murray,
Wentao Wei,
Yi Gao,
L. Dang,
M. Dorsch,
S. Agresta,
D. Schenkein,
S. Biller,
Shinsan M. Su,
S. de Botton,
K. Yen
|
9 |
2013 |
9
🐜
|
|
🐜
|
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.
26 auth.
R. Itzykson,
S. Thépot,
B. Quesnel,
F. Dreyfus,
O. Beyne-Rauzy,
P. Turlure,
N. Vey,
C. Récher,
C. Dartigeas,
L. Legros,
J. Delaunay,
C. Salanoubat,
Sorin Visanica,
A. Stamatoullas,
F. Isnard,
...
A. Marfaing‐Koka,
S. de Botton,
Y. Chelghoum,
A. Taksin,
I. Plantier,
S. Amé,
S. Boehrer,
C. Gardin,
C. L. Beach,
L. Adès,
P. Fenaux
|
8 |
2011 |
8
🐜
|
|
🐜
|
Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)
16 auth.
N. Boissel,
H. Leroy,
B. Brethon,
N. Philippe,
S. de Botton,
A. Auvrignon,
E. Raffoux,
T. Leblanc,
X. Thomas,
O. Hermine,
...
B. Quesnel,
A. Baruchel,
G. Leverger,
H. Dombret,
C. Preudhomme,
for the Acute Leukemia French Association and the Leuc Groups
|
8 |
2006 |
8
🐜
|
|
🐜
|
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.
41 auth.
K. Yen,
J. Travins,
F. Wang,
M. David,
Erin Artin,
K. Straley,
A. Padyana,
S. Gross,
B. Delabarre,
E. Tobin,
Yue Chen,
R. Nagaraja,
S. Choe,
Lei Jin,
Z. Konteatis,
...
Giovanni Cianchetta,
J. Saunders,
F. Salituro,
C. Quivoron,
P. Opolon,
O. Bawa,
V. Saada,
A. Paci,
S. Broutin,
O. Bernard,
S. de Botton,
B. Marteyn,
M. Pilichowska,
Yingxia Xu,
Cheng Fang,
F. Jiang,
Wentao Wei,
Shengfang Jin,
L. Silverman,
Wei Liu,
Hua Yang,
L. Dang,
M. Dorsch,
V. Penard-Lacronique,
S. Biller,
Shinsan M. Su
|
8 |
2017 |
8
🐜
|
|
🐜
|
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
37 auth.
Janeta Popovici-Muller,
R. Lemieux,
Erin Artin,
J. Saunders,
F. Salituro,
J. Travins,
Giovanni Cianchetta,
Z. Cai,
Ding Zhou,
D. Cui,
Ping Chen,
K. Straley,
E. Tobin,
F. Wang,
M. David,
...
V. Penard-Lacronique,
C. Quivoron,
V. Saada,
S. de Botton,
S. Gross,
L. Dang,
Hua Yang,
L. Utley,
Yue Chen,
HyeRyun Kim,
Shengfang Jin,
Zhiwei Gu,
Gui Yao,
Zhiyong Luo,
Xiaobing Lv,
Cheng Fang,
Liping Yan,
A. Olaharski,
L. Silverman,
S. Biller,
Shinsan M. Su,
K. Yen
|
8 |
2018 |
8
🐜
|
|
🐜
|
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.
18 auth.
M. Amatangelo,
L. Quek,
A. Shih,
E. Stein,
M. Roshal,
M. David,
B. Marteyn,
N. Farnoud,
S. de Botton,
O. Bernard,
...
Bin Wu,
K. Yen,
M. Tallman,
E. Papaemmanuil,
V. Penard-Lacronique,
A. Thakurta,
P. Vyas,
R. Levine
|
8 |
2017 |
8
🐜
|
|
🐜
|
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
31 auth.
G. Roboz,
C. Dinardo,
E. Stein,
S. de Botton,
A. Mims,
G. Prince,
J. Altman,
M. Arellano,
W. Donnellan,
H. Erba,
G. Mannis,
D. Pollyea,
A. Stein,
G. Uy,
J. Watts,
...
A. Fathi,
H. Kantarjian,
M. Tallman,
S. Choe,
D. Dai,
Bin Fan,
Hongfang Wang,
V. Zhang,
K. Yen,
S. Kapsalis,
D. Hickman,
Hua Liu,
S. Agresta,
Bin Wu,
E. Attar,
R. Stone
|
8 |
2019 |
8
🐜
|
|
🐢
|
Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.
27 auth.
E. Stein,
C. Dinardo,
A. Fathi,
D. Pollyea,
R. Stone,
J. Altman,
G. Roboz,
M. Patel,
R. Collins,
I. Flinn,
M. Sekeres,
A. Stein,
H. Kantarjian,
R. Levine,
P. Vyas,
...
K. Macbeth,
A. Tosolini,
Jason VanOostendorp,
Qiang Xu,
I. Gupta,
T. Lila,
A. Risueño,
K. Yen,
Bin Wu,
E. Attar,
M. Tallman,
S. de Botton
|
8 |
2019 |
8
🐢
|
|
🐜
|
Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience.
25 auth.
L. Adès,
A. Guerci,
E. Raffoux,
M. Sanz,
P. Chevallier,
S. Lapusan,
C. Récher,
X. Thomas,
C. Rayón,
S. Castaigne,
O. Tournilhac,
S. de Botton,
N. Ifrah,
J. Cahn,
E. Solary,
...
C. Gardin,
N. Fegeux,
D. Bordessoule,
A. Ferrant,
S. Meyer‐Monard,
N. Vey,
H. Dombret,
L. Degos,
S. Chevret,
P. Fenaux
|
8 |
2009 |
8
🐜
|
|
🐜
|
Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.
25 auth.
F. Damm,
O. Kosmider,
V. Gelsi-Boyer,
Aline Renneville,
N. Carbuccia,
Claire E Hidalgo-Curtis,
V. Della Valle,
L. Couronné,
L. Scourzic,
V. Chesnais,
A. Guerci-Bresler,
B. Slama,
O. Beyne-Rauzy,
A. Schmidt-Tanguy,
A. Stamatoullas-Bastard,
...
F. Dreyfus,
T. Prebet,
S. de Botton,
N. Vey,
M. Morgan,
N. Cross,
C. Preudhomme,
D. Birnbaum,
O. Bernard,
M. Fontenay
|
7 |
2012 |
7
🐜
|
